Literature DB >> 18197430

Antimicrobial effects of the saliva substitute, Oralbalance, against microorganisms from oral mucosa in the hematopoietic cell transplantation period.

Yuko Sugiura1, Yoshihiko Soga, Ichiro Tanimoto, Susumu Kokeguchi, Sachiko Nishide, Kotoe Kono, Kanayo Takahashi, Nobuharu Fujii, Fumihiko Ishimaru, Mitsune Tanimoto, Kokoro Yamabe, Soichiro Tsutani, Fusanori Nishimura, Shogo Takashiba.   

Abstract

GOALS: The commercially available saliva substitute Oralbalance has been reported to alleviate symptoms of post-radiotherapy xerostomia in head and neck cancer patients. Oralbalance may also be effective for xerostomia in patients undergoing hematopoietic cell transplantation (HCT) with high-dose chemotherapy and total-body irradiation. However, HCT patients are severely compromised, and saliva substitute must therefore not promote infection. This study was performed to determine the effects of Oralbalance on microbial species identified during HCT. PATIENTS AND METHODS: Microbial identification of oral mucosa was performed in 28 patients undergoing HCT. The antimicrobial effects of Oralbalance against bacteria and fungi detected in the HCT period were examined in vitro. Briefly, bacteria and fungi were spread on agar plates, and 0.1g of Oralbalance gel was applied (about phi1cm). After incubation at 37 degrees C for 24h, the presence of a transparent zone of inhibition around Oralbalance was observed. MAIN
RESULTS: Not only bacterial species constituting normal flora of the oral mucosa but also those not usually constituting normal flora, e.g., coagulase-negative Staphylococcus, were detected. A transparent zone was observed around Oralbalance in all bacterial species examined. No transparent zone was observed for Candida albicans, but growth was inhibited in the area where Oralbalance was applied.
CONCLUSIONS: Oralbalance does not facilitate increases in microorganisms in the HCT period. Oral care with Oralbalance does not promote infection in patients undergoing HCT.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18197430     DOI: 10.1007/s00520-007-0391-z

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  8 in total

Review 1.  Antimicrobial function of human saliva--how important is it for oral health?

Authors:  J Tenovuo
Journal:  Acta Odontol Scand       Date:  1998-10       Impact factor: 2.331

2.  A double-blind, crossover study of Biotène Oralbalance and BioXtra systems as salivary substitutes in patients with post-radiotherapy xerostomia.

Authors:  S A Shahdad; C Taylor; S C Barclay; I N Steen; P M Preshaw
Journal:  Eur J Cancer Care (Engl)       Date:  2005-09       Impact factor: 2.520

3.  A phase II study of Biotene in the treatment of postradiation xerostomia in patients with head and neck cancer.

Authors:  P Warde; B Kroll; B O'Sullivan; J Aslanidis; E Tew-George; J Waldron; W Maxymiw; F F Liu; D Payne; B Cummings
Journal:  Support Care Cancer       Date:  2000-05       Impact factor: 3.603

4.  Origins of Staphylococcus epidermidis and Streptococcus oralis causing bacteraemia in a bone marrow transplant patient.

Authors:  H F Kennedy; D Morrison; M E Kaufmann; M S Jackson; J Bagg; B E S Gibson; C G Gemmell; J R Michie
Journal:  J Med Microbiol       Date:  2000-04       Impact factor: 2.472

5.  Severe infection caused by Stomatococcus mucilaginosus in a neutropenic patient: case report and review of the literature.

Authors:  D Gruson; G Hilbert; A Pigneux; F Vargas; O Guisset; J Texier; J M Boiron; J Reiffers; G Gbikpi-Benissan; J P Cardinaud
Journal:  Hematol Cell Ther       Date:  1998-08

6.  Bacteremia due to Stomatococcus mucilaginosus in neutropenic patients in the setting of a cancer institute.

Authors:  P Fanourgiakis; A Georgala; M Vekemans; D Daneau; C Heymans; M Aoun
Journal:  Clin Microbiol Infect       Date:  2003-10       Impact factor: 8.067

Review 7.  Update on clinical significance of coagulase-negative staphylococci.

Authors:  W E Kloos; T L Bannerman
Journal:  Clin Microbiol Rev       Date:  1994-01       Impact factor: 26.132

8.  Viridans streptococcal bacteraemia in patients with neutropenia.

Authors:  P Richard; G Amador Del Valle; P Moreau; N Milpied; M P Felice; T Daeschler; J L Harousseau; H Richet
Journal:  Lancet       Date:  1995-06-24       Impact factor: 79.321

  8 in total
  8 in total

1.  Evaluation of xerostomia in hematopoietic cell transplantation by a simple capacitance method device.

Authors:  Yuko Sugiura; Yoshihiko Soga; Sachiko Nishide; Kotoe Kono; Kanayo Takahashi; Nobuharu Fujii; Fumihiko Ishimaru; Mitsune Tanimoto; Fusanori Nishimura; Shogo Takashiba
Journal:  Support Care Cancer       Date:  2008-06-05       Impact factor: 3.603

2.  With regard to our manuscripts on the commercial saliva substitute, Oralbalance®--its formula has been changed.

Authors:  Yuko Sugiura; Yoshihiko Soga; Ichiro Tanimoto; Susumu Kokeguchi; Sachiko Morishige-Nishide; Kotoe Itami-Kono; Kanayo Takahashi; Nobuharu Fujii; Fumihiko Ishimaru; Mitsune Tanimoto; Kokoro Yamabe; Soichiro Tsutani; Fusanori Nishimura; Shogo Takashiba
Journal:  Support Care Cancer       Date:  2014-09-20       Impact factor: 3.603

3.  Progress of oral care and reduction of oral mucositis--a pilot study in a hematopoietic stem cell transplantation ward.

Authors:  Yoshihiko Soga; Yuko Sugiura; Kanayo Takahashi; Hitomi Nishimoto; Yoshinobu Maeda; Mitsune Tanimoto; Shogo Takashiba
Journal:  Support Care Cancer       Date:  2010-09-15       Impact factor: 3.603

4.  Total bacterial counts on oral mucosa after using a commercial saliva substitute in patients undergoing hematopoietic cell transplantation.

Authors:  Yuko Sugiura; Yoshihiko Soga; Kokoro Yamabe; Soichiro Tsutani; Ichiro Tanimoto; Hiroshi Maeda; Susumu Kokeguchi; Nobuharu Fujii; Fumihiko Ishimaru; Mitsune Tanimoto; Fusanori Nishimura; Shogo Takashiba
Journal:  Support Care Cancer       Date:  2009-12-05       Impact factor: 3.603

Review 5.  Saliva substitutes for the treatment of radiation-induced xerostomia--a review.

Authors:  Sebastian Hahnel; Michael Behr; Gerhard Handel; Ralf Bürgers
Journal:  Support Care Cancer       Date:  2009-06-04       Impact factor: 3.603

6.  Oral mucositis in patients receiving reduced-intensity regimens for allogeneic hematopoietic cell transplantation: comparison with conventional regimen.

Authors:  Kanayo Takahashi; Yoshihiko Soga; Yumeno Murayama; Mika Udagawa; Hitomi Nishimoto; Yuko Sugiura; Yoshinobu Maeda; Mitsune Tanimoto; Shogo Takashiba
Journal:  Support Care Cancer       Date:  2009-04-23       Impact factor: 3.603

7.  The effect of two artificial salivas on the adhesion of Candida albicans to heat-polymerized acrylic resin.

Authors:  Burcin Oncul; Duygu Karakis; Funda Dogruman Al
Journal:  J Adv Prosthodont       Date:  2015-04-23       Impact factor: 1.904

8.  Effects of professional oral health care on reducing the risk of chemotherapy-induced oral mucositis.

Authors:  Hirokazu Saito; Yutaka Watanabe; Kazumichi Sato; Hiroaki Ikawa; Yoshifumi Yoshida; Akira Katakura; Shin Takayama; Michio Sato
Journal:  Support Care Cancer       Date:  2014-05-23       Impact factor: 3.603

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.